TNF and rheumatic disorder: Some studies have shown that the administration of tumor necrosis factor (TNF)-α inhibitors (TNFi), such as infliximab (IFX), etanercept (ETN) and adalimumab (ADA) improves insulin resistance in patients with rheumatic disease [17–21], while others have reported contradictory findings [22, 23].